Pfizer's Incoming CEO Represents Pipeline Push Over Dealmaking
- Bourla will head drugmaker as it pivots from acquisitions
- Drugmaker says up to 15 drugs could reach $1 billion in sales
Photographer: Jamie McCarthy/Getty Images
This article is for subscribers only.
Albert Bourla helped build Pfizer Inc.’s growing pipeline of drugs. Now he’ll run the biggest U.S. pharmaceutical company as it banks on that channel for future sales.
The New-York-based drugmaker said Monday that company veteran Bourla will succeed Ian Read as chief executive officer next year, a change that brings continuity but also symbolizes Pfizer’s recent shift toward emphasizing its laboratory over a larger merger or acquisition.